SYN-Tech Chem & Pharm Co Ltd (1777) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SYN-Tech Chem & Pharm Co Ltd (1777) has a cash flow conversion efficiency ratio of 0.099x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$256.05 Million ≈ $8.07 Million USD) by net assets (NT$2.59 Billion ≈ $81.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
SYN-Tech Chem & Pharm Co Ltd - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how SYN-Tech Chem & Pharm Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read SYN-Tech Chem & Pharm Co Ltd debt and liabilities for a breakdown of total debt and financial obligations.
SYN-Tech Chem & Pharm Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SYN-Tech Chem & Pharm Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Broadband Technology Co Ltd
SHG:600608
|
0.572x |
|
Maiden Holdings Ltd
F:4OWA
|
-0.562x |
|
Wieson Technologies Co Ltd
TWO:6272
|
0.046x |
|
Jasa Armada Indonesia Tbk PT
JK:IPCM
|
0.112x |
|
Cherry Hill Mortgage Investment Corp
NYSE:CHMI
|
0.035x |
|
Hexa Tradex Limited
NSE:HEXATRADEX
|
0.000x |
|
Emeren Group Ltd
NYSE:SOL
|
0.106x |
|
WooriNet Inc
KQ:115440
|
0.037x |
Annual Cash Flow Conversion Efficiency for SYN-Tech Chem & Pharm Co Ltd (2015–2025)
The table below shows the annual cash flow conversion efficiency of SYN-Tech Chem & Pharm Co Ltd from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see 1777 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$2.59 Billion ≈ $81.61 Million |
NT$559.49 Million ≈ $17.63 Million |
0.216x | -11.18% |
| 2024-12-31 | NT$2.56 Billion ≈ $80.66 Million |
NT$622.61 Million ≈ $19.62 Million |
0.243x | +114.86% |
| 2023-12-31 | NT$2.32 Billion ≈ $73.01 Million |
NT$262.29 Million ≈ $8.26 Million |
0.113x | -43.27% |
| 2022-12-31 | NT$2.20 Billion ≈ $69.29 Million |
NT$438.81 Million ≈ $13.83 Million |
0.200x | +152.09% |
| 2021-12-31 | NT$1.98 Billion ≈ $62.49 Million |
NT$156.98 Million ≈ $4.95 Million |
0.079x | -69.24% |
| 2020-12-31 | NT$1.24 Billion ≈ $39.08 Million |
NT$319.21 Million ≈ $10.06 Million |
0.257x | +30.86% |
| 2019-12-31 | NT$1.16 Billion ≈ $36.55 Million |
NT$228.12 Million ≈ $7.19 Million |
0.197x | +14.63% |
| 2018-12-31 | NT$1.10 Billion ≈ $34.62 Million |
NT$188.49 Million ≈ $5.94 Million |
0.172x | +298.39% |
| 2017-12-31 | NT$996.24 Million ≈ $31.39 Million |
NT$42.89 Million ≈ $1.35 Million |
0.043x | -81.19% |
| 2016-12-31 | NT$1.03 Billion ≈ $32.37 Million |
NT$235.26 Million ≈ $7.41 Million |
0.229x | +48.07% |
| 2015-12-31 | NT$969.06 Million ≈ $30.53 Million |
NT$149.84 Million ≈ $4.72 Million |
0.155x | -- |
About SYN-Tech Chem & Pharm Co Ltd
SYN-TECH Chem. & Pharm. Co., Ltd. manufactures and sells active pharmaceutical ingredients (APIs) in Taiwan, Asia, Europe, the Americas, and internationally. The company offers test drugs and surfactants, as well as various Chinese, Western, and animal medicines. It also provides products in various categories, such as anticoagulant, attention deficit hyperactivity disorder, skeletal muscle relax… Read more